Multiple Time-Point 68Ga-PSMA I&T PET/CT for Characterization of Primary Prostate Cancer
Authors:
- Martin MamachMMMartin Mamach
- Florian WilkeFWFlorian Wilke
- Christoph A. von KlotCKChristoph A. von Klot
- Christoph HenkenberensCHChristoph Henkenberens
- James T. ThackerayJTJames T. Thackeray
- Jan M. SohnsJSJan M. Sohns
- Lilli GeworskiLGLilli Geworski
- Tobias L. RossTRTobias L. Ross
- Hans-Juergen WesterHWHans-Juergen Wester
- Hans ChristiansenHCHans Christiansen
- Frank M. BengelFBFrank M. Bengel
- 1 June 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 42 (6) , e286-e293
Abstract
The aims of this study were to gain mechanistic insights into prostate cancer biology using dynamic imaging and to evaluate the usefulness of multiple time-point 68Ga–prostate-specific membrane antigen (PSMA) I&T PET/CT for the assessment of primary prostate cancer before prostatectomy. Twenty patients with prostate cancer underwent 68Ga-PSMA I&T PET/CT before prostatectomy. The PET protocol consisted of early dynamic pelvic imaging, followed by static scans at 60 and 180 minutes postinjection (p.i.). SUVs, time-activity curves, quantitative analysis based on a 2-tissue compartment model, Patlak analysis, histopathology, and Gleason grading were compared between prostate cancer and benign prostate gland. Primary tumors were identified on both early dynamic and delayed imaging in 95% of patients. Tracer uptake was significantly higher in prostate cancer compared with benign prostate tissue at any time point (P ≤ 0.0003) and increased over time. Consequently, the tumor-to-nontumor ratio within the prostate gland improved over time (2.8 at 10 minutes vs 17.1 at 180 minutes p.i.). Tracer uptake at both 60 and 180 minutes p.i. was significantly higher in patients with higher Gleason scores (P < 0.01). The influx rate (Ki) was higher in prostate cancer than in reference prostate gland (0.055 [r = 0.998] vs 0.017 [r = 0.996]). Primary prostate cancer is readily identified on early dynamic and static delayed 68Ga-PSMA ligand PET images. The tumor-to-nontumor ratio in the prostate gland improves over time, supporting a role of delayed imaging for optimal visualization of prostate cancer.Keywords
This publication has 17 references indexed in Scilit:
- 68Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate CancerJournal of Nuclear Medicine, 2016
- 68Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2016
- 68Ga-HBED-CC-PSMA PET/CT Versus Histopathology In Primary Localized Prostate Cancer: A Voxel-Wise ComparisonTheranostics, 2016
- Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerInternational Journal of Biological Sciences, 2016
- Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical ProstatectomyJournal of Nuclear Medicine, 2015
- The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- PSMA as a target for radiolabelled small moleculesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesionsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2012
- Prostate cancer incidence and mortality trends in 37 European countries: An overviewEuropean Journal of Cancer, 2010
- A Novel Cytoplasmic Tail MXXXL Motif Mediates the Internalization of Prostate-specific Membrane AntigenMolecular Biology of the Cell, 2003